Triglyceride News and Research

RSS

Triglycerides are a type of fat in the bloodstream and fat tissue. Too much of this type of fat can contribute to the hardening and narrowing of your arteries. This puts you at risk of having a heart attack or stroke. Diseases such as diabetes, obesity, kidney failure or alcoholism can cause high triglycerides. Often, high triglycerides occur along with high levels of cholesterol, another type of fat. Triglycerides are measured along with cholesterol as part of a blood test. Normal triglyceride levels are below 150. Levels above 200 are high.

Nordic Naturals launches one-per-day omega-3 fatty acid gels

Nordic Naturals introduces Daily Omega, a line of three products that offers a simple solution for consumers concerned about what type of product to take on a regular basis to address their need for omega-3 essential fatty acids.

25 Jan 2011

Study may help develop novel ways to combat lipotoxic cardiomyopathy, related heart disease

A team led by Rolf Bodmer, Ph.D. at Sanford-Burnham Medical Research Institute recently unraveled an alternative pathway to lipotoxic cardiomyopathy in fruit flies - a genetic mechanism that occurs independently of a diet high in fat.

19 Jan 2011

5 easy steps to improve heart health

Did you know that a good night's sleep can help prevent heart disease? There are many simple ways to lower your risk.

12 Jan 2011

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States.

12 Jan 2011

Teenagers who consume excess sugar may face risk of developing heart disease

Teenagers who consume a lot of added sugars in soft drinks and foods may have poor cholesterol profiles — which may possibly lead to heart disease in adulthood, according to first-of-its-kind research reported in Circulation: Journal of the American Heart Association.

11 Jan 2011

Positive PK study results from ECLIPSE trial against cardiovascular disease

Omthera Pharmaceuticals, a privately-held emerging specialty pharmaceuticals company, today announced data from its ECLIPSE trial, designed to evaluate the bioavailability of Epanova™, the Company's lead compound for the treatment of very high triglycerides, in comparison to Lovaza®, the leading prescription Omega 3.

10 Jan 2011

Tomatoes contain nutrient which prevents vascular diseases

They are the most widely produced fruit in the world and now scientists in Japan have discovered that tomatoes contain a nutrient which could tackle the onset of vascular diseases. The research, published in the journal Molecular Nutrition & Food Research, reveals that an extracted compound, 9-oxo-octadecadienoic, has anti-dyslipidemic affects.

6 Jan 2011

Positive topline results from ZGN-433 Phase 1b study in obesity patients

Zafgen, a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced positive topline results from its Phase 1b study of ZGN-433, a methionine aminopeptidase 2 inhibitor, for the treatment of severe obesity.

6 Jan 2011

Betulin in birch bark appears to provide metabolic benefits

An ingredient found in abundance in birch bark appears to have an array of metabolic benefits, according to new studies in animals that are reported in the January issue of Cell Metabolism, a Cell Press publication.

5 Jan 2011

Lifestyle changes between childhood and adulthood linked to high-risk cholesterol levels

Lifestyle changes between childhood and adulthood appear associated with whether an individual will maintain, improve or develop high-risk cholesterol levels, according to a report in the January issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

4 Jan 2011

Isis commences ISIS-APOCIIIRx Phase 1 trial in hypertriglyceridemia

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-APOCIIIRx, an antisense drug designed to lower triglycerides to treat a variety of diseases associated with elevated triglycerides. Hypertriglyceridemia, a condition characterized by elevated levels of triglycerides, is an independent risk factor for cardiovascular disease and is a component of numerous cardiovascular and metabolic diseases, including metabolic syndrome.

21 Dec 2010

Amylin submits metreleptin rolling submission BLA for treatment of rare forms of lipodystrophy

Amylin Pharmaceuticals, Inc. today announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.

21 Dec 2010

Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported the completion of patient randomization for its ANCHOR trial, a pivotal Phase 3 trial of AMR101. The Company indicated that it anticipates reporting top-line results from this trial in Q2 2011.

16 Dec 2010

Smoking is common among young adults and children with diabetes, raises risk of heart disease

Cigarette smoking is widespread among children and young adults with diabetes yet few health care providers are counseling children and young adults with diabetes to not smoke or stop smoking, according to a new report from the SEARCH Study Group, published online in the Journal of Pediatrics.

7 Dec 2010

Spherix announces results of D-tagatose Phase 3 trial for Type 2 diabetes

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced results from its first Phase 3 trial post hoc analysis in which the higher body mass index (BMI) of the U.S. population relative to the Indian population was a likely key contributor to the more positive effects of D-tagatose in the lowering of HbA1c levels in the U.S. population. Initial results were announced on October 7.

2 Dec 2010

Vitamin D supplementation may reduce risk of diabetes, heart disease: Research

Researchers from the UC Davis Health System have found that compared with healthy controls, blood levels of vitamin D are significantly reduced in patients in the Sacramento area with metabolic syndrome, a constellation of disease risk factors that affects about one in three U.S. adults and predisposes them to diabetes, heart disease and stroke.

1 Dec 2010

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101.

29 Nov 2010

Omthera reaches agreement with FDA on SPA for Epanova Phase III trial in patients with very high triglycerides

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the design of its planned Phase III registration clinical trial of Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega 3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

22 Nov 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

Despite progress in testing Americans for HIV, lack of federal/private insurance impedes expansion

With projections that human immunodeficiency virus (HIV) infection rates are increasing in some populations, former Surgeon General Dr. C. Everett Koop -- who charted the nation's policies on HIV/AIDS following the first deaths from AIDS in 1981 -- today issued a stern warning to the public health community: HIV/AIDS continues to be a major epidemic and requires a national mobilization to identify and provide immediate care for many Americans with HIV who remain undiagnosed -- an estimated 200,000 people.

18 Nov 2010

Triglyceride News and Research

Further Reading

Nordic Naturals launches one-per-day omega-3 fatty acid gels

Study may help develop novel ways to combat lipotoxic cardiomyopathy, related heart disease

5 easy steps to improve heart health

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Teenagers who consume excess sugar may face risk of developing heart disease

Positive PK study results from ECLIPSE trial against cardiovascular disease

Tomatoes contain nutrient which prevents vascular diseases

Positive topline results from ZGN-433 Phase 1b study in obesity patients

Betulin in birch bark appears to provide metabolic benefits

Lifestyle changes between childhood and adulthood linked to high-risk cholesterol levels

Isis commences ISIS-APOCIIIRx Phase 1 trial in hypertriglyceridemia

Amylin submits metreleptin rolling submission BLA for treatment of rare forms of lipodystrophy

Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels

Smoking is common among young adults and children with diabetes, raises risk of heart disease

Spherix announces results of D-tagatose Phase 3 trial for Type 2 diabetes

Vitamin D supplementation may reduce risk of diabetes, heart disease: Research

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides

Omthera reaches agreement with FDA on SPA for Epanova Phase III trial in patients with very high triglycerides

VYTORIN reduces major vascular events in patients with chronic kidney disease

Despite progress in testing Americans for HIV, lack of federal/private insurance impedes expansion

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News